[go: up one dir, main page]

MX2012002466A - Compuestos novedosos de tetrahidroisoquinolina. - Google Patents

Compuestos novedosos de tetrahidroisoquinolina.

Info

Publication number
MX2012002466A
MX2012002466A MX2012002466A MX2012002466A MX2012002466A MX 2012002466 A MX2012002466 A MX 2012002466A MX 2012002466 A MX2012002466 A MX 2012002466A MX 2012002466 A MX2012002466 A MX 2012002466A MX 2012002466 A MX2012002466 A MX 2012002466A
Authority
MX
Mexico
Prior art keywords
ureido
dihydro
carboxylate
carboxymethyl
phenyl
Prior art date
Application number
MX2012002466A
Other languages
English (en)
Inventor
Yoshikazu Uto
Hiroshi Karasawa
Kiyosumi Takaishi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2012002466A publication Critical patent/MX2012002466A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

La presente invención se refiere a un compuesto o a una sal farmacológicamente aceptable del mismo que tiene un efecto inhibitorio de DGAT y efecto supresor de la alimentación excelentes; la presente invención proporciona éster 4-carboximetil-ciclohexílico de ácido trans-6-[3-(2,4-difluoro-fen il)-ureido]-3,4-dihidro-1H-isoquinolin-2-carboxílico, éster 4-carboximetil-ciclohexílico de ácido trans-6-[3-(2-cloro-fenil)-u reido]-3,4-dihidro-1H-isoquinolin-2-carboxílico, éster 4-carboximetil-ciclohexílico de ácido trans-6-[3-(2,3-difluoro-fen il)-ureido]-3,4-dihidro-1H-isoquinolin-2-carboxílico, éster 4-carboximetil-ciclohexílico de ácido trans-6-[3-(2,5-difluoro-fen il)-ureido]-3,4-dihidro-1H-isoquinolin-2-carboxilico, éster 4-carboximetil-ciclohexílico de ácido trans-6-[3-(2,6-difluoro-fen il)-ureido]-3,4-dihidro-1H-isoquinolin-2-carboxílico, o similares, o una sal farmacológicamente aceptable de los mismos.
MX2012002466A 2009-08-28 2010-08-27 Compuestos novedosos de tetrahidroisoquinolina. MX2012002466A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009198540 2009-08-28
PCT/JP2010/064550 WO2011024932A1 (ja) 2009-08-28 2010-08-27 新規テトラヒドロイソキノリン化合物

Publications (1)

Publication Number Publication Date
MX2012002466A true MX2012002466A (es) 2012-03-14

Family

ID=43628031

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002466A MX2012002466A (es) 2009-08-28 2010-08-27 Compuestos novedosos de tetrahidroisoquinolina.

Country Status (18)

Country Link
US (1) US20120202847A1 (es)
EP (1) EP2471777A4 (es)
JP (1) JPWO2011024932A1 (es)
KR (1) KR20120067333A (es)
CN (1) CN102471276A (es)
AU (1) AU2010287464A1 (es)
BR (1) BR112012004487A2 (es)
CA (1) CA2790390A1 (es)
CO (1) CO6430504A2 (es)
IL (1) IL218331A0 (es)
IN (1) IN2012DN01203A (es)
MX (1) MX2012002466A (es)
NZ (1) NZ598535A (es)
RU (1) RU2012111837A (es)
SG (1) SG178299A1 (es)
TW (1) TW201109306A (es)
WO (1) WO2011024932A1 (es)
ZA (1) ZA201200956B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9242929B2 (en) 2011-05-20 2016-01-26 Glaxosmithkline Intellectual Property (No.2) Limited Compounds as diacylglycerol acyltransferase inhibitors
WO2012165398A1 (ja) * 2011-05-30 2012-12-06 第一三共株式会社 シクロアルキルオキシビアリール型化合物
JP2014521617A (ja) 2011-07-26 2014-08-28 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング バニロイド受容体リガンドとしての置換二環性芳香族カルボキサミドおよび尿素誘導体
EP3188730B1 (en) 2014-09-05 2019-05-01 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
EP3188731B1 (en) 2014-09-05 2019-04-03 Merck Sharp & Dohme Corp. Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
WO2016036633A1 (en) * 2014-09-05 2016-03-10 Merck Sharp & Dohme Corp. Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006045209A (ja) * 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
AU2005260495B2 (en) 2004-07-02 2009-04-30 Sankyo Company, Limited Urea derivative
CN101076524A (zh) * 2004-10-12 2007-11-21 法马科皮亚药物研发公司 作为选择性黑色素浓集激素受体拮抗剂的治疗肥胖和相关病症的双环化合物
WO2007074753A1 (ja) * 2005-12-27 2007-07-05 Daiichi Sankyo Company, Limited 置換されたウレア誘導体を含有する医薬
RU2474575C2 (ru) * 2008-03-26 2013-02-10 Дайити Санкио Компани, Лимитед Новое производное тетрагидроизохинолина, фармацевтическая композиция на его основе, применение его и способ лечения и/или предотвращения заболевания

Also Published As

Publication number Publication date
SG178299A1 (en) 2012-03-29
CO6430504A2 (es) 2012-04-30
RU2012111837A (ru) 2013-10-10
IN2012DN01203A (es) 2015-04-10
EP2471777A4 (en) 2013-01-02
BR112012004487A2 (pt) 2016-03-22
US20120202847A1 (en) 2012-08-09
WO2011024932A1 (ja) 2011-03-03
CN102471276A (zh) 2012-05-23
EP2471777A1 (en) 2012-07-04
IL218331A0 (en) 2012-04-30
TW201109306A (en) 2011-03-16
ZA201200956B (en) 2012-10-31
KR20120067333A (ko) 2012-06-25
CA2790390A1 (en) 2011-03-03
JPWO2011024932A1 (ja) 2013-01-31
AU2010287464A1 (en) 2012-03-15
NZ598535A (en) 2013-07-26

Similar Documents

Publication Publication Date Title
MY165728A (en) Selective glycosidase inhibitors and uses thereof
TW200603834A (en) Film products having controlled disintegration properties
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
TW200612958A (en) Substituted imidazole derivatives
NZ595212A (en) Liposome composition
IL195341A0 (en) Methods and materials for making simvastatin and related compounds
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2012002466A (es) Compuestos novedosos de tetrahidroisoquinolina.
MY143698A (en) Substituted morpholine and thiomorpholine derivatives.
TNSN08191A1 (en) Kinase inhibitors
MY161461A (en) Akt and p70 s6 kinase inhibitors
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MX2011006254A (es) Composiciones aclaradoras de la piel con inhibidores de acetilcolinesterasa.
WO2011096676A3 (en) Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
TN2012000105A1 (en) Spirolactam derivatives and uses of same
EA201000434A1 (ru) Сокристаллы пириметанила и дитианона
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
UA103996C2 (en) Ivabradine hydrobromide
GB201020397D0 (en) Compounds
MX2011011899A (es) Metodo para reducir los niveles proteicos ubiquitinados.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal